Skip to main content

Advertisement

SpringerLink
Log in

Integrating New Therapies in the Treatment of Advanced Melanoma

  • Skin Cancer (WH Sharfman, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Treatments for advanced melanoma have evolved rapidly based on improved understanding of the pathways that determine T-cell responses and knowledge of growth-related mutations, which can be targeted with new classes of pharmacologic agents. The FDA approved ipilimumab and vemurafenib for advanced melanoma in 2011. Our practice is to evaluate all tumors from patients with metastatic disease for the presence of a BRAF mutation (Fig. 1). More than 20 years of follow-up show that responders to IL-2 can be cured of their melanoma. Therefore, we recommend high-dose IL-2 as first line therapy for patients with excellent functional status and normal cardiopulmonary reserve regardless of their BRAF mutation status. We use ipilimumab, which can induce durable tumor regressions and improved survival, as initial therapy for patients who refuse or are not candidates for IL-2, also regardless of their BRAF mutation status. Ipilimumab can be used as salvage therapy for patients with advanced disease after IL-2 or vemurafenib. Targeted therapies such as vemurafenib or imatinib can be offered to patients whose melanomas express the BRAF V600E or C-Kit mutations. Vemurafenib is particularly useful for patients whose disease is progressing rapidly, as clinical improvement can be obtained within days of starting therapy and response rates may be as high as 70 %. The major reason we do not recommend vemurafenib as first line treatment in all patients whose tumors have BRAF mutations is the short median duration of response of approximately 7 months. Enrollment in a clinical trial should always be considered for patients with metastatic melanoma. The clinical trial focus has changed from finding any agent with activity in melanoma, to overcoming mechanisms of resistance and enhancing the immunomodulatory activity of these new agents that confer therapeutic benefit. Selected patients can benefit from surgical resection or radiation to manage oligometastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Spiegel R, Naishadham D, Jemal A. CA Cancer J Clin. 2012;62:10–1.

    Article  Google Scholar 

  2. Jemal A, Tiwari RC, Murray T, et al. American Cancer, Cancer statistics. CA Cancer J Clin. 2004;54:8–29.

    Article  PubMed  Google Scholar 

  3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    Article  PubMed  Google Scholar 

  4. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51.

    PubMed  CAS  Google Scholar 

  5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. The first randomized trial to show that treatment with ipilimumab improves survival in patients with advanced melanoma. This is the first agent to improve survival in this patient population.

    Article  PubMed  CAS  Google Scholar 

  6. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. Provides confirmation of ipilimumab’s surval benefit in untreated patients compared to standard drug therapy. Provides further evidence of durability of benefit and ipilimumab’s safety.

    Article  PubMed  CAS  Google Scholar 

  7. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19. First demonstration that inhibition of the MAP kinase pathway with a BRAF inhibitor leads to rapid reponses in a majority of patients with advanced melanoma whose tumors contain a BRAF mutation.

    Article  PubMed  CAS  Google Scholar 

  8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. Randomized study shows for the first time that treatment with the BRAF inhibitor, vemurafenib, improves survival compared to standard therapy. It provides useful information on the spectrum of toxicity, including the development of keratoacanthoma or squamous cell cancer of the skin in 20 % of vemurafenib-treated patients.

    Article  PubMed  CAS  Google Scholar 

  9. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–92.

    Article  PubMed  CAS  Google Scholar 

  10. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16.

    PubMed  CAS  Google Scholar 

  11. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–27. Confirmation of the benefit of interleukin-2 and first suggestion that addition of a vaccine improves clinical outcome.

    Article  PubMed  CAS  Google Scholar 

  12. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.

    Article  PubMed  CAS  Google Scholar 

  13. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–7. Study shows long-term durability of complete responders from a series of trials using T-cell transfer following lymphodepletion in patients with advanced melanoma.

    Article  PubMed  CAS  Google Scholar 

  14. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645–52.

    Article  PubMed  CAS  Google Scholar 

  15. Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012;35:66–72.

    Article  PubMed  CAS  Google Scholar 

  16. Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res. 2011;17:7440–50.

    Article  PubMed  CAS  Google Scholar 

  17. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262:909–11.

    Article  PubMed  CAS  Google Scholar 

  18. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533–46.

    Article  PubMed  CAS  Google Scholar 

  19. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–8.

    Article  PubMed  CAS  Google Scholar 

  20. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.

    Article  PubMed  CAS  Google Scholar 

  21. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn. 2011;13:504–13.

    Article  PubMed  Google Scholar 

  22. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14:6821–8.

    Article  PubMed  CAS  Google Scholar 

  23. Su F, Bradley WD, Wang Q, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 2012;72:969–78. Identifies mechanism by which melanoma cells acquire resistance to vemurafenib.

    Article  PubMed  CAS  Google Scholar 

  24. Atefi M, von Euw E, Attar N, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2012;6:e28973.

    Article  Google Scholar 

  25. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14. Clinical trial of vemurafenib with the longest followup demonstrated impressive improvement in median overall survival.

    Article  PubMed  CAS  Google Scholar 

  26. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207–15. This paper describes the mechanism by which patients develop squamous cell cancers of the skin during treatment with the BRAF inhibitor, vemurafenib.

    Article  PubMed  CAS  Google Scholar 

  27. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904–9.

    Article  PubMed  CAS  Google Scholar 

  28. Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib Therapy for Melanoma Patients with KIT Mutations. Clin Cancer Res. 2012;18:1457–63.

    Article  PubMed  CAS  Google Scholar 

  29. Seung SK, Sneed PK, McDermott MW, et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am. 1998;4:103–9.

    PubMed  CAS  Google Scholar 

  30. Hara W, Tran P, Li G, et al. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery. 2009;64:A26–32.

    Article  PubMed  Google Scholar 

  31. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.

    Article  PubMed  CAS  Google Scholar 

  32. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583–90.

    Article  PubMed  CAS  Google Scholar 

  33. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012. doi:10.1016/S1470-2045(12)70090-6. ePub Mar 27.

  34. Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104:111–5.

    Article  PubMed  Google Scholar 

  35. Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133:104–10.

    Article  PubMed  Google Scholar 

  36. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res. 2012;18:33–9. Most up-to-date descriptions of the variety of ways melanoma cells have developed resistance following BRAF inhibition.

    Article  PubMed  CAS  Google Scholar 

  37. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20.

    Article  PubMed  CAS  Google Scholar 

  38. Wang H, Daouti S, Li WH, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res. 2011;71:5535–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

B.D.C.: Consultancy for Bristol-Myers Squibb and Prometheus Pharmaceuticals, payment for development of educational presentations from Prometheus Pharmaceutical and Genentech, travel/accommodations expenses covered or reimbursed from Bristol-Myers Squibb and Prometheus Pharmaceutical. W.J.U: board membership to SAIC-Frederick, National Cancer Institute, and Bristol-Myers Squibb, consultancy for Bristol-Myers Squibb, honoraria from Bristol-Myers Squibb, travel/accommodations expenses covered or reimbursed from Bristol-Myers Squibb, National Cancer Institute, and SAIC-Frederick.

Author information

Authors and Affiliations

  1. Providence Cancer Center, 4805 NE Glisan St, Ste 2N35, Portland, OR, 97213, USA

    Brendan D. Curti MD & Walter J. Urba MD, PhD

Authors
  1. Brendan D. Curti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter J. Urba MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brendan D. Curti MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curti, B.D., Urba, W.J. Integrating New Therapies in the Treatment of Advanced Melanoma. Curr. Treat. Options in Oncol. 13, 327–339 (2012). https://doi.org/10.1007/s11864-012-0201-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0201-9

Keywords

Search

Navigation